Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609675 | 1.00 | CYP26A1 (0.49) | CYP26A1ACP3L3MBTL1CTSAITGB1 | |
| SCHEMBL27797767 | 0.84 | CYP26A1 (0.50) | CYP26A1ACP3L3MBTL1CTSAATM | |
| SCHEMBL9085971 | 0.82 | FFAR1 (0.50) | CYP26A1ACP3L3MBTL1CTSAITGB1 | |
| SCHEMBL9152199 | 0.82 | CTSA (0.52) | CYP26A1ACP3L3MBTL1CTSAATM | |
| SCHEMBL2743434 | 0.81 | ACP3 (0.44) | CYP26A1ACP3TAAR1FFAR1SLC6A9 | |
| SCHEMBL29700706 | 0.81 | L3MBTL1 (0.43) | ACP3L3MBTL1TAAR1 | |
| SCHEMBL2858374 | 0.81 | KMT2A (0.55) | CYP26A1ACP3L3MBTL1CTSAATM | |
| SCHEMBL2060444 | 0.81 | CYP26A1 (0.48) | CYP26A1ACP3L3MBTL1CTSAATM | |
| SCHEMBL27347770 | 0.81 | KMT2A (0.55) | CYP26A1ACP3L3MBTL1CTSAATM | |
| SCHEMBL3510648 | 0.81 | KMT2A (0.55) | CYP26A1ACP3L3MBTL1CTSAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | CYP26A1 1762/4885ACP3 727/4885L3MBTL1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.